YCS22· OtherEugit Therapeutics
Enabling Tissue Targeting of Therapies
Founders
Not read from YC yet; the weekly run fills these in.
Same space
Competitors
Closest in what they build, same category.
SynsoryBioW24"If-then" conditional logic for protein drugsShared: synthetic biology, therapeutics, oncologyActive
AlixiaW22Targeting the Tumor Ecosystem to address cancer drug resistance.Shared: therapeutics, oncology, biotechnologyActive
Modulari-TW23We teach your immune system to attack and cure cancerShared: cell therapy, synthetic biology, oncologyActive
Dorian TherapeuticsS18New therapeutics to rejuvenate tissue and treat age-related diseasesShared: therapeuticsAcquired
Promakhos TherapeuticsS21A therapeutics platform for curing inflammatory disordersShared: therapeuticsActive
Adjacent
Overlapping tags, a different niche.
Granza BioW24Building programmable therapeutics for the immune systemShared: synthetic biology, therapeutics, oncologyActive
Sensible BiotechnologiesS21Unlocking the next generation of mRNA medicinesShared: synthetic biology, therapeutics, biotechnologyActive
Kopra BioS24Genetically engineered viruses that teach your immune system to kill…Shared: synthetic biology, therapeutics, oncologyActive
Eris BiotechW24Our drugs engage the immune system to fight tumorsShared: therapeutics, oncologyActive
Abalone BioW20We create activating antibodies to treat diseases others can’t.Shared: synthetic biology, therapeuticsActive
Also from S22
Batchmates in Summer 2022.
Serinus BiosciencesS22Combinations therapy by rational designActive
Birch BiosciencesS22We recycle plastic using engineered enzymesActive
KeylikaS22Redefining the Standard of Care for Iron Deficiency AnemiaActive
100xS22Create, Share, and Monetize AI AgentsActive
AccessOwlS22Managing your Employees' Access to SaaSActive
ActivepiecesS22Open-source, AI-first and no-code business automation toolActive
About Eugit Therapeutics
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
San Francisco, CA, USA; South San Francisco, CA, USA
Eugit Therapeutics: questions
Which YC batch was Eugit Therapeutics in?
Eugit Therapeutics was in Y Combinator's Summer 2022 batch (S22).
Is Eugit Therapeutics still active?
Y Combinator lists Eugit Therapeutics as active.
Where is Eugit Therapeutics based?
Eugit Therapeutics lists San Francisco, CA, USA; South San Francisco, CA, USA as its location on YC's directory.
Not affiliated with Y Combinator. From YC's public directory. Logos via logo.dev; trademarks belong to their owners.